CAG-Luc-2A-GFP AAV (Serotype AAV-BI30)

CAG-Luc-2A-GFP AAV (serotype AAV-BI30) is a recombinant adeno-associated virus vector designed for efficient dual reporting. This vector contains a CAG (CMV early enhancer/chicken β-actin) hybrid promoter that simultaneously drives the expression of firefly luciferase (Luc) and green fluorescent protein (GFP) via a self-cleaving 2A peptide linker. The AAV-BI30 serotype exhibits superior tropism for both neuronal and non-neuronal cells, with enhanced blood-brain barrier penetration compared to traditional serotypes. Its non-pathogenic nature, stable episomal existence, and low immunogenicity make it ideal for long-term studies. This vector achieves over 90% co-expression efficiency of Luc (quantitative bioluminescent tracking) and GFP (visual cell labeling), enabling multimodal detection across various scales, from in vivo imaging to single-cell microscopy. With an approximate 4.7kb packaging capacity and high-titer production, it surpasses lentiviral vectors in terms of safety and translational applications.

This versatile tool accelerates preclinical research in neurobiology, oncology, and gene therapy development. In neuroscience, the CNS targeting capabilities of the AAV-BI30 serotype enable optogenetic behavioral studies and simultaneous Luc-based quantitative analysis of neuronal activity. Cancer researchers utilize the dual reporting system to monitor metastasis (via bioluminescent imaging) while precisely localizing micrometastases (GFP fluorescence). The construct’s 2A-mediated stoichiometric expression is particularly valuable for: 1) CRISPR delivery validation (GFP+ cells indicate successful editing, while Luc reports on functional outcomes), 2) Stem cell lineage tracing in regenerative medicine, and 3) High-throughput screening of gene therapies—where Luc provides rapid readouts and GFP facilitates cell sorting.